Path AI / award

About

The Forbes AI 50 recognizes the most promising privately held companies using artificial intelligence. As a result of SVM’s submission, PathAI was selected for the 2024 list.

For a company bringing AI into clinical pathology, recognition alongside the most prominent names in AI signals credibility to health systems, biopharma partners, and investors. The honor is part of SVM’s broader awards program for PathAI.